Meeting
2024 ASCO Annual Meeting
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
Authors
Jie Liu
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Jie Liu , Yaotiao Deng , Ying Wang , Jie Zhang , Mei Li , Yu Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
ChiCTR2300067650
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11561)
DOI
10.1200/JCO.2024.42.16_suppl.11561
Abstract #
11561
Poster Bd #
487
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
First Author: Xi Guo
Poster
2021 ASCO Annual Meeting
Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.
First Author: Jiayong Liu
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
First Author: Qin Xu
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon